Drug intelligence / Profile preview

复方薏薢颗粒

Development stage: Unknown
Lead developer: Humanwell Healthcare
Administration: Oral

Overview

复方薏薢颗粒 (Fufang Yixie Keli) is a traditional Chinese medicine (TCM) oral granule developed by Wuhan Humanwell Hi-Tech Industry. It is specifically indicated for the treatment of non-acute gout and hyperuricemia in patients presenting with the TCM syndrome of dampness-turbidity-stasis obstruction (湿浊瘀阻证). The formulation is designed to lower serum uric acid levels and prevent gout flares by addressing the underlying TCM pathology of dampness and blood stasis. It is currently in Phase 3 clinical trials in China.

Other names: Compound Yiba GranulesFufang Yixie KeliCompound Yixie Granules

Beyond the preview

Go deeper on 复方薏薢颗粒.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 复方薏薢颗粒.

Explore the full profile